Staging prostate cancer is essential for guiding treatment decisions and achieving optimal outcomes. A clinical trial demonstrated that conventional imaging underdetects metastatic disease compared to prostate-specific membrane antigen-positron emission tomography (PSMA-PET). To explore this further, a study examined staging information obtained by PSMA-PET/computed tomography in 182 patients with high-risk biochemically recurrent hormone-sensitive prostate cancer.
In the study, PSMA-PET yielded positive results in 84% of patients. Remarkably, PSMA-PET detected distant metastatic disease in 46% of patients and polymetastatic disease in 24%, both of which were classified as nonmetastatic by conventional imaging. Detection rates varied by prior treatments: after definitive radiotherapy (92% positive & 56% distant metastases), radical prostatectomy and salvage radiotherapy (85% positive &…
